Evogene (NASDAQ:EVGN) and The Mosaic (NYSE:MOS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Insider & Institutional Ownership
33.0% of Evogene shares are held by institutional investors. Comparatively, 69.8% of The Mosaic shares are held by institutional investors. 0.5% of The Mosaic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Evogene and The Mosaic's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Evogene | -2,649.69% | -38.40% | -32.43% |
The Mosaic | -13.05% | N/A | N/A |
Analyst Ratings
This is a summary of current recommendations and price targets for Evogene and The Mosaic, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Evogene | 0 | 0 | 1 | 0 | 3.00 |
The Mosaic | 1 | 8 | 10 | 0 | 2.47 |
Evogene presently has a consensus target price of $9.00, suggesting a potential upside of 105.95%. The Mosaic has a consensus target price of $27.9722, suggesting a potential downside of 16.40%. Given Evogene's stronger consensus rating and higher probable upside, analysts plainly believe Evogene is more favorable than The Mosaic.
Valuation & Earnings
This table compares Evogene and The Mosaic's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Evogene | $750,000.00 | 150.04 | $-18,110,000.00 | ($0.70) | -6.24 |
The Mosaic | $8.91 billion | 1.42 | $-1,067,400,000.00 | $0.19 | 176.11 |
Evogene has higher earnings, but lower revenue than The Mosaic. Evogene is trading at a lower price-to-earnings ratio than The Mosaic, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Evogene has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, The Mosaic has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.
Summary
The Mosaic beats Evogene on 9 of the 14 factors compared between the two stocks.